Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study.

ABSTRACT:

Purpose

The PARP inhibitor rucaparib is approved in the United States for patients with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious germline and/or somatic BRCA1 or BRCA2 (BRCA) alteration. While sequencing of tumor tissue is considered the standard for identifying patients with BRCA alterations (BRCA⁺), plasma profiling may provide a minimally invasive option to select patients for rucaparib treatment. Here, we report clinical efficacy in patients with BRCA⁺ mCRPC identified through central plasma, central tissue, or local genomic testing and enrolled in TRITON2.

Patients and methods

Patients had progressed after next-generation androgen receptor-directed and taxane-based therapies for mCRPC and had BRCA alte

SUBMITTER: Loehr A 

PROVIDER: S-EPMC8678310 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature